{
    "id": 1294,
    "fullName": "FGFR2 rearrange",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2 rearrangement indicates an unspecified rearrangement of the FGFR2 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "rearrange",
    "createDate": "08/05/2014",
    "updateDate": "04/19/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14368,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TAS-120 treatment resulted in partial response in 2 patients with cholangiocarcinoma harboring FGFR2 rearrangements (Annals of Oncology, Volume 29, Issue suppl_5).",
            "molecularProfile": {
                "id": 1317,
                "profileName": "FGFR2 rearrange"
            },
            "therapy": {
                "id": 1053,
                "therapyName": "Futibatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11611,
                    "pubMedId": null,
                    "title": "Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_5/mdy149/5039476"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15142,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (FIGHT-202) trial, Pemigatinib (INCB054828) treatment resulted in partial response in 18% (8/45, 1 unconfirmed complete response), stable disease in 58% (26/45) of patients with cholangiocarcinoma harboring FGFR2 translocations, with a median progression-free survival of 6.8 months; and no response were observed in cohorts of patients with other FGF/FGFR genetic alterations or wild-type FGF/FGFR (Ann Oncol, Oct 2018, 29 (suppl 8), abstract 756P; NCT02924376).",
            "molecularProfile": {
                "id": 1317,
                "profileName": "FGFR2 rearrange"
            },
            "therapy": {
                "id": 4173,
                "therapyName": "Pemigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12689,
                    "pubMedId": null,
                    "title": "Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF recepto",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_8/mdy282.139/5142016"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14369,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TAS-120 treatment resulted in partial response in a patient with cholangiocarcinoma harboring FGFR2 rearrangement and FGFR2 amplification (Annals of Oncology, Volume 29, Issue suppl_5).",
            "molecularProfile": {
                "id": 29989,
                "profileName": "FGFR2 amp FGFR2 rearrange"
            },
            "therapy": {
                "id": 1053,
                "therapyName": "Futibatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11611,
                    "pubMedId": null,
                    "title": "Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_5/mdy149/5039476"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1317,
            "profileName": "FGFR2 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29989,
            "profileName": "FGFR2 amp FGFR2 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}